 |
How
to why to guide: continuous subcutaneous insulin infusion (insulin
pump therapy) |
| |
This online guide informs clinicians, commissioners
and managers how to successfully implement insulin pump therapy
into routine clinical and operational practice (NHS) |
| |
|
|
GlaxoSmithKline
statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone) |
| |
GlaxoSmithKline confirmed today that a joint
advisory committee to the U.S. Food and Drug Administration (FDA)
voted to allow Avandia to remain on the market (GSK) |
| |
|
|
European
Medicines Agency starts review of rosiglitazone-containing medicines |
| |
New studies question cardiovascular safety of
anti-diabetes medicines (European Medicines Agency) |
| |
|
|
Prevalence
and healthcare costs of diabetic retinopathy: a population-based
register study in Sweden |
| |
Approximately one-third of patients with diabetes
have some form of DR. Average healthcare costs increase considerably
with the severity of DR, which suggests that preventing progression
of DR may lower healthcare costs (Diabetologia) |
| |
|
|
Incretin
agents in type 2 diabetes |
| |
Clinical Review (College of Family Physicians
of Canada) |
| |
|
| |
|
| |
|
| |
|
|
Successful
treatment of Charcot foot |
| |
A surgical technique that secures foot bones
with an external frame has enabled more than 90 percent of patients
to walk normally again (Loyola University Health System) |
| |
|
|
Pre-Diabetes
Symptoms Not Linked to Cognitive Decline |
| |
In elderly without diabetes, high fasting glucose,
insulin resistance not tied to cognitive impairment (Modern Medicine) |
| |
|
|
Exenatide
therapy in insulin-treated type 2 diabetes and obesity |
| |
Exenatide therapy in insulin-treated type 2
diabetes and obesity was associated with very significant reductions
in weight and insulin doses. Exenatide should be considered in
people with type 2 diabetes on insulin and have obesity, weight
gain and poor glycaemic control (QJM) |
| |
|
|
Hypusine:
a New Target for Therapeutic Intervention in Diabetic Inflammation |
| |
Because the hypusine modification is absolutely
required for eIF5A action in cytokine signaling, we propose that
this modification could serve as a new drug target for islet ß cell protection in the setting of diabetic inflammation (Discovery Medicine) |
| |
|
|
Insulin
resistance is associated with increased cholesterol synthesis,
decreased cholesterol absorption and enhanced lipid response
to statin therapy |
| |
Insulin-resistant patients have superior LDL-C
responses to statin therapy and that this may be related to increased
cholesterol synthesis (Atherosclerosis) |
| |
|
